6 recruiting, 3 active not recruiting, 2 completed, 1 not yet recruiting. 7 Phase 2, 6 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 3, Active not recruiting 2, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 6 | Recruiting 3, Active not recruiting 2, Completed 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow Unresectable Urothelial Carcinoma: new trials by email Literature Review of Unresectable Urothelial Carcinoma trials Research Report on Unresectable Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma Enfortumab vedotin, Pembrolizumab - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Recruiting | Fox Chase Cancer Center | 97 | 2026-01-23 | 2026-02-19 |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer Biospecimen Collection, Carboplatin, Cisplatin - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-12-02 | 2026-10-05 |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 27 | 2025-05-05 | 2026-09-21 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma Belinostat, Durvalumab - Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma | Phase 1 | Completed | University of Utah | 7 | 2022-01-14 | 2026-10-14 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Cisplatin, Elimusertib, Gemcitabine Hydrochloride - Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 74 | 2021-08-25 | 2026-07-31 |
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment - Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma | Phase 1 | Recruiting | Emory University | 32 | 2021-07-23 | 2026-04-29 |
| Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) Pemigatinib, Pembrolizumab, Gemcitabine - Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | Phase 2 | Terminated | Incyte Corporation | 7 | 2020-05-14 | 2025-11-04 |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
| Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 171 | 2006-10-23 | 2026-09-09 |
Carcinoma, Transitional Cell (12) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Lung Neoplasms (3) · Melanoma (3) · Neoplasm Metastasis (3) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Merkel Cell (2) · Colorectal Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Acrocephalosyndactylia (1)
Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms, Glandular and Epithelial (13) · Carcinoma (12) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Neoplasms by Site (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Urologic Diseases (5) · Urologic Neoplasms (5) · Genital Diseases (4) · Lung Diseases (4) · Respiratory Tract Diseases (4)
pembrolizumab (5) · Gemcitabine (4) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · 1,2-diaminocyclohexaneplatinum II citrate (3) · Cisplatin (3) · Immunoglobulin G (3) · Nivolumab (3) · Platinum (3) · Biopsy (2) · Carboplatin (2) · Disulfides (2) · enfortumab vedotin (2) · BAY 1895344 (1) · Bevacizumab (1)
National Cancer Institute (NCI) (5) · Mayo Clinic (2) · Emory University (1) · Fox Chase Cancer Center (1) · Fred Hutchinson Cancer Center (1) · Incyte Corporation (1) · M.D. Anderson Cancer Center (1) · University of Utah (1)
United States (12) · Canada (2) · Austria (1) · Belgium (1) · Finland (1) · France (1) · Germany (1) · Ireland (1) · Italy (1) · Japan (1) · Poland (1) · Portugal (1) · Puerto Rico (1) · Romania (1) · Slovakia (1)
David I Quinn (1) · Jonathan E Rosenberg (1) · Luis Feliz Vinas, MD (1) · Mamta Parikh (1) · Matthew D Galsky (1) · Mehmet A Bilen, MD (1) · Monika Joshi (1) · Pooja Ghatalia, MD (1) · Roxana S. Dronca, M.D. (1) · Sangeeta Goswami (1) · Shailender Bhatia, MD (1) · Sumati V Gupta (1) · Yanyan Lou, MD, PhD (1)
PMID 33989025, PMID 40256659, PMID 40591902
UM1CA186717 (2), 2019 (1), N01CM00038 (1), N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P30CA033572 (1), P30CA138292 (1), U01CA062505 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1), UM1CA186705 (1)